Healthcare Industry News: Bionovo
News Release - May 31, 2007
Rob Frankenberg, Ph.D. Joins Bionovo as Vice President of Drug ManufacturingEMERYVILLE, Calif., May 31 (HSMN NewsFeed) -- Bionovo, Inc. (Nasdaq: BNVI ), announced the hiring of Rob Frankenberg, Ph.D., PMP as Vice President of Drug Manufacturing. Dr. Frankenberg brings 15 years of Chemistry, Manufacturing and Controls (CMC) experience to support the clinical production of the company's pipeline of drugs addressing women's health issues and cancer including its lead drug candidates, MF101, for the treatment of hot flashes in menopausal women, VG101, for the treatment of vaginal dryness, and BZL101 and AA102 for the treatment of advanced breast cancer.
Dr. Frankenberg, formerly with Bayer HealthCare, has held a variety of technical and senior project management positions. He was a lead developer of the purification process for Bayer's Kogenate-FS and was integral to the current Good Manufacturing Practice (cGMP) regulations of clinical and licensed production of biotechnology products. Dr. Frankenberg has experience in working with worldwide regulatory authorities for new product development and post-licensure process changes. Most recently, Dr. Frankenberg was the Senior Project Manager, CMO/CRO Manager and CMC Manufacturing Lead for the development of Bayer's long acting Liposomal Kogenate product.
Dr. Frankenberg received his B.S. in biochemistry from the University of California, Davis and earned his Ph.D. from the University of California, San Francisco/University of California, Berkeley Joint Graduate Group in Bioengineering with an emphasis in biochemical engineering. In addition, Dr. Frankenberg is a graduate of UC Berkeley's Management of Technology Program and is a certified Project Management Professional.
"We are excited to add Dr. Frankenberg as Vice President of Drug Manufacturing to our team," said Isaac Cohen, Bionovo's co-founder and CEO. "His experience and expertise in drug manufacturing and regulatory compliance will enhance our ability to create cGMPs for the production of our drugs as we move to late stage clinical development."
Bionovo is a drug development company focusing on the discovery of novel pharmaceutical agents for cancer and women's health. The company has two drugs in clinical testing. MF101 has completed Phase 2 for quality of life conditions associated with menopause, and BZL101 is in Phase 1/2 for the treatment of advanced breast cancer. The company has an additional pipeline of drugs in development for breast cancer, pancreatic cancer and other menopausal symptoms. The company is developing its products in close collaboration with leading U.S. academic research centers, including: University of California, San Francisco, University of Colorado Health Sciences Center, University of California, Berkeley, and the University of Texas Southwestern Medical Center. For further information please visit: http://www.Bionovo.com.
This release contains certain forward-looking statements relating to the business of Bionovo, Inc. that can be identified by the use of forward-looking terminology such as "believes," "expects," or similar expressions. Such forward-looking statements involve known and unknown risks and uncertainties, including uncertainties relating to product development, efficacy and safety, regulatory actions or delays, the ability to obtain or maintain patent or other proprietary intellectual property protection, market acceptance, physician acceptance, third-party reimbursement, future capital requirements, competition in general and other factors that may cause actual results to be materially different from those described herein as anticipated, believed, estimated or expected. Certain of these risks and uncertainties are or will be described in greater detail in our filings with the Securities and Exchange Commission, which are available at http://www.sec.gov. Bionovo, Inc. is under no obligation (and expressly disclaims any such obligation) to update or alter its forward-looking statements whether as a result of new information, future events or otherwise.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.